Transmission Ultrasound Breast Imaging to Become Available in EMEA Markets
QT Imaging signs distribution agreement with Freedom Ventures for its FDA-cleared breast scanner
Jan 07, 2021, 08:41 ET
NOVATO, Calif., Jan. 7, 2021 /PRNewswire/ -- QT Imaging™, developer of the QTscan®, has selected Freedom Ventures B.V., as the exclusive distributor of its 3D breast imaging technology for the European, Middle Eastern and North African markets. Freedom Ventures, a Dutch company which will do business as QT Scan BV, is well established in the field of medical devices, with an extensive network of distributers, and a Center of Excellence for technical, marketing, and clinical training.
"As a small company, working with an established distribution network provides us global market reach while being able to maintain the level of quality in marketing, sales, technical service, and most importantly patient care, that we have established in the US. Freedom Ventures has the experience to be that partner in this important region," says Meg Donigan, Chief Operating Officer at QT Imaging. Freedom Ventures will also assist QT Imaging in securing a CE Mark and manage the registration process in its markets.
The European medical imaging market, currently valued at $38 Billion, is expected to grow almost 10% annually over the next decade, with advancements in medical imaging technology driving that increased demand. QT's medical imaging technology generates 3D images with remarkable accuracy and precision, and the volumetric images are produced without the need of contrast injections or radiation. The QTscan® is an FDA-cleared breast imaging tool, and the company will seek CE marking to provide confidence to the healthcare community that the device meets EU safety, health, and environmental protection requirements before market launch.
Rutger Brest van Kempen, CEO of Freedom Ventures, says "We're very excited about the opportunity the radiation-free QTscan has to fill a unique need in the European breast imaging market where women are being screened later and less frequently due to concerns about radiation. In the Middle East and North Africa, this new technology will also be embraced for its ease of adoption as it requires no costly facilities or special licensing for operators. Hisham Hasaan, Freedom Ventures Vice-President for the Middle East and Africa says, "With QTscan we will have a huge opportunity to screen woman, who now have to travel far to hospitals where radiology equipment is available whereas our technologies can be installed virtually anywhere. We will focus on creating regional QTscan centers to bring this unique technology to the masses."
About QT Ultrasound
QT Imaging™ is a privately held company engaged in the research, development, and commercialization of an innovative automated imaging system producing high-resolution transmission ultrasound images. The company has received FDA 510(K) clearance for its QT Imaging Breast Scanner, and the National Institutes of Health (NIH) awarded over $15 million in funding to continue QT Imaging research. The company's clinical trials have been conducted at prestigious institutions in the US and Europe.
The QT Imaging Breast Scanner is indicated for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient's breast. The device is not intended to be used as a replacement for screening mammography.
For more information about QT Imaging, visit qtimaging.com.
Media Contact:
Michaela Kalff
415 497 1339
[email protected]
SOURCE QT Imaging, Inc.
